Aarti Pharmalabs reports a decline in FY26 consolidated profit to Rs 1,747 million, impacted by USD forward contract fair value adjustments. Despite the dip, the company is aggressive on growth, targeting a 15-18% revenue and EBITDA CAGR over the next four years. Expansion is anchored by the Atali Greenfield project and the Tarapur unit, with new R&D investments in TIDES technology starting in FY27.
Aarti Pharmalabs FY26 Performance and Growth Strategy
Consolidated Revenue stood at Rs 18,194 million for FY26, with PAT reaching Rs 1,747 million.
Reader Takeaway: Heavy capital expenditure in greenfield projects signals long-term ambition despite recent accounting-driven margin and profit volatility.
What just happened
Aarti Pharmalabs has released its FY26 financial results showing a 14% year-on-year decline in consolidated operational revenue to Rs 18,194 million. Profits were notably impacted by fair value movements on long-dated USD forward contracts, leading to a 35.9% drop in consolidated PAT to Rs 1,747 million. The company clarified that results are not strictly comparable to FY25 due to the reclassification of Ganesh Polychem as a joint venture effective April 1, 2025.
Why this matters
The company is in a heavy investment phase. Management has set a growth target of 15-18% revenue and EBITDA CAGR over the next three to four years. This strategy relies on balancing significant capital outflows for new infrastructure with the hope of scaling up its CDMO and CMO business segments.
Capex and Strategic Investments
Investment remains at the core of the company's forward-looking strategy:
- Atali Greenfield Project: A Rs 400 crore investment with 80% capacity of the first block already operationalized by Q4 FY26.
- Tarapur Expansion: A Rs 210 crore brownfield project in Maharashtra that adds 9,000 MTPA in capacity for Xanthine derivatives, specifically targeting beverage sector customers.
- New R&D: The company is initiating investments in TIDES (Peptides and Oligonucleotides) in FY27 to diversify its product portfolio.
Risks to watch
Investors should monitor the impact of currency volatility, which caused significant valuation adjustments in the current fiscal year. Furthermore, the reliance on aggressive capital expenditure requires strong execution to ensure that the new capacities at Atali and Tarapur achieve the targeted return on investment in a competitive pharmaceutical market.
What to track next
Watch for the progress of the Atali Block 2 groundbreaking, slated for Q3 FY27. Additionally, monitor how efficiently the new Tarapur unit integrates into the supply chain to drive volume growth in the coming quarters.